iCAD
ICAD develops and delivers cancer detection and radiation therapy solutions, and services that enable clinicians to find and treat cancers.
Launch date
Employees
Market cap
€36.4m
Enterprise valuation
€18m (Public information from Sep 2024)
Share price
$1.56 ICAD
Nashua New Hampshire (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 29.7m | 33.6m | 27.9m | 17.3m | 19.2m | 23.9m | 29.0m |
| % growth | (5 %) | 13 % | (17 %) | (38 %) | 11 % | 24 % | 21 % |
| EBITDA | (16.2m) | (10.2m) | (13.2m) | (6.6m) | (6.0m) | - | - |
| % EBITDA margin | (54 %) | (30 %) | (47 %) | (38 %) | (31 %) | - | - |
| Profit | (17.6m) | (11.2m) | (13.7m) | (4.8m) | (7.1m) | (5.8m) | (2.6m) |
| % profit margin | (59 %) | (33 %) | (49 %) | (28 %) | (37 %) | (24 %) | (9 %) |
| EV / revenue | 10.2x | 5.4x | 1.7x | 2.7x | 2.2x | 1.8x | 1.5x |
| EV / EBITDA | -18.8x | -17.8x | -3.5x | -7.1x | -7.1x | - | - |
| R&D budget | 8.1m | 9.2m | 8.6m | 5.2m | - | - | - |
| R&D % of revenue | 27 % | 27 % | 31 % | 30 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | $15.0m | Post IPO Debt | |
| N/A | $12.5m | Post IPO Equity | |
| N/A | $22.0m | Post IPO Equity | |
| Total Funding | - | ||
